Back to search
Hemolytic-Uremic Syndrome, Atypical
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hemolytic-Uremic Syndrome, Atypical trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hemolytic-Uremic Syndrome, Atypical trials you may qualify forThe purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study parti…
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic sy…
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed…
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases…
This project aims to identify, through RNA-Seq technology, the genetic alterations underlying undiagnosed rare diseases in pediatric and adult patients with ear…
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various cl…
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatme…
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric…
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.